Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + Low-Dose Lenalidomide vs Ixazomib Alone for Maintenance in High-Risk Multiple Myeloma
NCT05722405Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of lenalidomide in multiple myeloma (MM), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Jul 2022; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05722405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05722405.